Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: -106.00 (-0.87%)
Spread: 2.00 (0.017%)
Open: 12,092.00
High: 12,178.00
Low: 12,010.00
Prev. Close: 12,156.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

FOREX-U.S. dollar slumps as equity markets rally; Fed in focus

Mon, 14th Sep 2020 15:20

* Suga set to succeed Abe as Japan PM, focus turns to new cabinet
* Dollar falls to two-week low vs yen
* Dollar under pressure ahead of Fed policy meeting outcome on Wed
* Graphic: World FX rates in 2020 https://tmsnrt.rs/2RBWI5E

(Adds new comment, FX table, updates prices, changes byline, dateline; previous LONDON)
By Gertrude Chavez-Dreyfuss
NEW YORK, Sept 14 (Reuters) - The dollar slipped on Monday against its major peers, dropping to a
two-week low versus the yen, as positive news about a COVID-19 vaccine and a wave of merger and
acquisition deals lifted the mood in global equity markets.
Investors also looked ahead to an event-packed week which includes a Federal Reserve meeting and the
appointment of a new Japanese premier.
U.S. stocks rose on Monday on signs of progress in developing a COVID-19 vaccine and a flurry of
multibillion-dollar deals, including reports of Oracle winning the battle for the U.S. arm of
TikTok.
"As equities trade more positively at the start of the new week, the dollar is trading weaker again.
The market is still showing that it is likely to fade any dollar strength," said Vassili Serebriakov, FX
strategist at UBS in New York.
Global equities got a lift after drugmaker AstraZeneca resumed its British clinical trials of
its COVID-19 vaccine, one of the most advanced in development.
"As long as the market perceives that the market is moving in the right direction with the vaccine,
the dollar will weaken more as a cyclical play," Serebriakov added.
In morning trading, the dollar index fell 0.4% to 92.919, after posting two straight weeks of
gains.
This week's Fed Reserve meeting will be its first since Chairman Jerome Powell unveiled a policy shift
toward greater tolerance of inflation, effectively pledging to keep interest rates low for longer.
"There will be pressure on the Fed to back up the new policy goals with some action," said MUFG
strategist Lee Hardman, noting that inflation remained well below target.
"Expectations are they could strengthen forward guidance, possibly by saying rates will be on hold for
3-4 years," said Hardman, who remains bearish on the greenback.
Analysts at Standard Chartered said there was a risk the Fed would disappoint dollar bears.
Speculators trimmed net short dollar positions for the second straight week to $32.67 billion,
according to Reuters calculations and Commodity Futures Trading Commission data. That's off nine-year
highs of $33.68 billion in late August.
The dollar fell 0.5% against the yen to 105.66 yen, after earlier sliding to a two-week low.
The Bank of Japan's meeting on Thursday is not expected to yield any policy changes but the bank may
be quizzed on whether it could follow the Fed's inflation stance.
On the political front, Chief Cabinet Secretary Yoshihide Suga was picked to head Japan's ruling party
on Monday, meaning on Wednesday in parliament he is set to be selected by his peers as prime minister,
taking over from Shinzo Abe.
Suga has vowed to continue Abe's policies.
The euro was up 0.3% versus the dollar at $1.1880.
The single currency had spiked to a one-week high above $1.191 after Thursday's European Central Bank
meeting, before easing back as policymakers talked it down the next day.

========================================================
Currency bid prices at 10:10AM (1410 GMT)
Description RIC Last U.S. Close Pct Change YTD Pct High Bid Low Bid
Previous Change
Session
Euro/Dollar EUR= $1.1879 $1.1845 +0.29% +5.97% +1.1887 +1.1831
Dollar/Yen JPY= 105.6400 106.1400 -0.47% -2.96% +106.1900 +105.6400
Euro/Yen EURJPY= 125.51 125.75 -0.19% +2.92% +125.9000 +125.5300
Dollar/Swiss CHF= 0.9059 0.9086 -0.30% -6.40% +0.9098 +0.9060
Sterling/Dollar GBP= 1.2901 1.2793 +0.84% -2.70% +1.2918 +1.2778
Dollar/Canadian CAD= 1.3169 1.3174 -0.04% +1.41% +1.3196 +1.3154
Australian/Doll AUD= 0.7294 0.7283 +0.15% +3.89% +0.7295 +0.7265
ar
Euro/Swiss EURCHF= 1.0763 1.0764 -0.01% -0.82% +1.0775 +1.0761
Euro/Sterling EURGBP= 0.9206 0.9254 -0.52% +8.90% +0.9263 +0.9202
NZ NZD= 0.6707 0.6664 +0.65% -0.43% +0.6714 +0.6660
Dollar/Dollar
Dollar/Norway NOK= 8.9874 9.0336 -0.51% +2.38% +9.0531 +8.9861
Euro/Norway EURNOK= 10.6787 10.7024 -0.22% +8.55% +10.7121 +10.6716
Dollar/Sweden SEK= 8.7595 8.7687 +0.17% -6.29% +8.7881 +8.7539
Euro/Sweden EURSEK= 10.4090 10.3916 +0.17% -0.58% +10.4210 +10.3756


(Reporting by Gertrude Chavez-Dreyfuss; Additional reporting by Sujata Rao and Ritvik Carvalho in London;
editing by Jonathan Oatis)

More News
8 Feb 2024 08:59

LONDON MARKET OPEN: Unilever up on buyback; BAT ups dividend

(Alliance News) - THE FTSE 100 in London opened slightly higher on Thursday, with earnings from British American Tobacco and Unilever boosting the index.

Read more
8 Feb 2024 08:44

TOP NEWS: AstraZeneca confident after 2023 profit more than doubles

(Alliance News) - AstraZeneca PLC on Thursday said it expects another year of strong growth after reporting pretax profit in 2023 more than doubled.

Read more
8 Feb 2024 07:58

AstraZeneca shares slip as Q4 profits miss forecasts

(Sharecast News) - Biopharma titan AstraZeneca delivered a 6% increase in sales in 2023 despite a $3.7bn decline in Covid-19 medicines revenues, as it guided to a strong pick-up in growth this year - though profits came in slightly under analysts' forecasts.

Read more
8 Feb 2024 07:50

LONDON BRIEFING: Unilever sets new buyback; Astra profit surges

(Alliance News) - Stocks in London are called to open slightly higher on Thursday, as investors eye a busy day of earnings.

Read more
2 Feb 2024 08:38

AstraZeneca celebrates latest successful trial of acoramidis in Japan

(Alliance News) - AstraZeneca PLC on Friday said positive results from a Phase 3 trial of acoramidis are consistent with global findings, bring the drug closer to regulatory submission in Japan.

Read more
2 Feb 2024 06:22

TOP NEWS: US sends drugmakers initial offers in Medicare price talks

(Alliance News) - The US government said it was making initial offers to drugmakers Thursday as part of Medicare negotiations meant to lower the prices many older Americans would pay for 10 medicines.

Read more
1 Feb 2024 15:52

UK earnings, trading statements calendar - next 7 days

Friday 2 February 
YouGov PLCTrading Statement
Monday 5 February 
Home REIT PLCTrading Statement
Porvair PLCFull Year Results
Trident Royalties PLCTrading Statement
Vodafone Group PLCTrading Statement
Tuesday 6 February 
Alumasc Group PLCHalf Year Results
BP PLCFull Year Results
Filtronic PLCHalf Year Results
Mattioli Woods PLCHalf Year Results
Renishaw PLCHalf Year Results
Virgin Money UK PLCTrading Statement
Wednesday 7 February 
Ashmore Group PLCHalf Year Results
Barratt Developments PLCHalf Year Results
HydrogenOne Capital Growth PLCTrading Statement
Phoenix Spree Deutschland LtdTrading Statement
PZ Cussons PLCHalf Year Results
Smurfit Kappa Group PLCFull Year Results
UK Commercial Property REIT LtdTrading Statement
Thursday 8 February 
Anglo American PLCTrading Statement
AstraZeneca PLCFull Year Results
British American Tobacco PLCFull Year Results
Compass Group PLCTrading Statement
Redrow PLCHalf Year Results
SSE PLCTrading Statement
Unilever PLCFull Year Results
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
29 Jan 2024 08:19

TOP NEWS: AstraZeneca, Daiichi's Enhertu granted priority review in US

(Alliance News) - AstraZeneca PLC on Monday said its cancer drug conjugate received priority review by the Food & Drug Administration in the US for patients with metastatic HER2-positive solid tumours.

Read more
22 Jan 2024 11:45

BioNTech challenges AstraZeneca with breast cancer precision drug trial

FRANKFURT, Jan 22 (Reuters) - BioNTech and its partner Duality Biologics said on Monday they initiated a late-stage trial testing their precision drug against a certain type of breast cancer, taking on a rival partnership between AstraZeneca and Daiichi Sankyo.

Read more
19 Jan 2024 09:28

TOP NEWS: AstraZeneca's Voydeya receives approval in Japan for PNH

(Alliance News) - AstraZeneca PLC on Friday said its inhibitor Voydeya, also known as danicopan, received approval in Japan for adults with paroxysmal nocturnal haemoglobinuria, or PNH.

Read more
16 Jan 2024 17:17

FTSE 100 hits one-month low, precious miners biggest drag

FTSE 100 down 0.5%, FTSE 250 flat

*

Read more
16 Jan 2024 16:17

London close: Stocks finish lower as wage growth eases

(Sharecast News) - London's stock markets finished in the red on Tuesday, as investors assessed the latest UK jobs data.

Read more
16 Jan 2024 11:58

LONDON MARKET MIDDAY: FTSE 100 falls despite cooler UK wage growth

(Alliance News) - The FTSE 100 in London was down at midday Tuesday, as investors nervously eye Wednesday's UK inflation data and what it will mean for interest rates.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.